Genetic variants in the glutathione S-transferase genes and survival in colorectal cancer patients after chemotherapy and differences according to treatment with oxaliplatin

Pharmacogenetics and Genomics

Volumn 24, Issue 7, 2014, Pages 340-347

  Kap, Elisabeth J ^a   Richter, Swantje ^a   Rudolph, Anja ^a   Jansen, Lina ^a   Ulrich, Alexis ^b   Hoffmeister, Michael ^a   Ulrich, Cornelia M ^c,d   Brenner, Hermann ^a   Chang Claude, Jenny ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^d Fred Hutchinson Cancer Research Center   (United States)

Author keywords

chemotherapy; colorectal cancer; GSTM1 CNV; GSTP1 ile105val; GSTT1 CNV; oxaliplatin

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CETUXIMAB; FLUOROURACIL; GLUTATHIONE TRANSFERASE; GLUTATHIONE TRANSFERASE M1; GLUTATHIONE TRANSFERASE P1; GLUTATHIONE TRANSFERASE T1; IRINOTECAN; OXALIPLATIN;

ADULT; AGED; ALLELE; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER GENETICS; CANCER LOCALIZATION; CANCER PALLIATIVE THERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; COLORECTAL CANCER; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; FLUORESCENCE ANALYSIS; GENE EXPRESSION; GENE FREQUENCY; GENETIC VARIABILITY; GENOTYPE; GERMANY; HAZARD RATIO; HIGH RESOLUTION MELTING ANALYSIS; HOMOZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; MULTIPLEX POLYMERASE CHAIN REACTION; OVERALL SURVIVAL; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CASE-CONTROL STUDIES; COLORECTAL NEOPLASMS; FEMALE; GENE DELETION; GENE DOSAGE; GENETIC VARIATION; GENOTYPE; GERMANY; GLUTATHIONE TRANSFERASE; HETEROZYGOTE; HOMOZYGOTE; HUMANS; MALE; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; PHARMACOGENETICS; POLYMORPHISM, GENETIC; PROPORTIONAL HAZARDS MODELS; TREATMENT OUTCOME;

EID: 84902285110     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0000000000000059     Document Type: Article

References (38)

1. Robert Koch-Institute (RKI) & Association of Population-bases Cancer Registries in Germany (GEKID). Cancer in Germany 2007/2008 (2012) RKI, Berlin.
2. Majek O, Gondos A, Jansen L, Emrich K, Holleczek B, Katalinic A, et al. Survival from colorectal cancer in Germany in the early 21st century. Br J Cancer 2012; 106: 1875-1880.
3. Kweekel DM, Gelderblom H, Guchelaar HJ. Pharmacology of oxaliplatin and the use of pharmacogenomics to individualize therapy. Cancer Treat Rev 2005; 31: 90-105.
4. Hayes JD, Strange RC. Glutathione S-transferase polymorphisms and their biological consequences. Pharmacology 2000; 61: 154-166.
5. Grothey A, Goldberg RM. A review of oxaliplatin and its clinical use in colorectal cancer. Expert Opin Pharmacother 2004; 5: 2159-2170.
6. Raymond E, Faivre S, Chaney S, Woynarowski J, Cvitkovic E. Cellular and molecular pharmacology of oxaliplatin. Mol Cancer Ther 2002; 1: 227-235.
7. Jones BA, Christensen AR, Wise JP Sr, Yu H. Glutathione S-transferase polymorphisms and survival in African-American and white colorectal cancer patients. Cancer Epidemiol 2009; 33: 249-256.
8. Stoehlmacher J, Park DJ, Zhang W, Yang D, Groshen S, Zahedy S, Lenz HJ. A multivariate analysis of genomic polymorphisms: prediction of clinical outcome to 5-FU/oxaliplatin combination chemotherapy in refractory colorectal cancer. Br J Cancer 2004; 91: 344-354.
9. Ruzzo A, Graziano F, Loupakis F, Rulli E, Canestrari E, Santini D, et al. Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy. J Clin Oncol 2007; 25: 1247-1254.
10. Lamas MJ, Duran G, Balboa E, Bernardez B, Touris M, Vidal Y, et al. Use of a comprehensive panel of biomarkers to predict response to a fluorouracil-oxaliplatin regimen in patients with metastatic colorectal cancer. Pharmacogenomics 2011; 12: 433-442.
11. Zarate R, Rodriguez J, Bandres E, Patiño-Garcia A, Ponz-Sarvise M, Viudez A, et al. Oxaliplatin, irinotecan and capecitabine as first-line therapy in metastatic colorectal cancer (mCRC): a dose-finding study and pharmacogenomic analysis. Br J Cancer 2010; 102: 987-994.
12. Holley SL, Rajagopal R, Hoban PR, Deakin M, Fawole AS, Elder JB, et al. Polymorphisms in the glutathione S-transferase mu cluster are associated with tumour progression and patient outcome in colorectal cancer. Int J Oncol 2006; 28: 231-236.
13. McLeod HL, Sargent DJ, Marsh S, Green EM, King CR, Fuchs CS, et al. Pharmacogenetic predictors of adverse events and response to chemotherapy in metastatic colorectal cancer: results from North American Gastrointestinal Intergroup Trial N9741. J Clin Oncol 2010; 28: 3227-3233.
14. Kweekel DM, Gelderblom H, Antonini NF, Van der Straaten T, Nortier JW, Punt CJ, Guchelaar HJ. Glutathione-S-transferase pi (GSTP1) codon 105 polymorphism is not associated with oxaliplatin efficacy or toxicity in advanced colorectal cancer patients. Eur J Cancer 2009; 45: 572-578.
15. Boige V, Mendiboure J, Pignon JP, Loriot MA, Castaing M, Barrois M, et al. Pharmacogenetic assessment of toxicity and outcome in patients with metastatic colorectal cancer treated with LV5FU2, FOLFOX, and FOLFIRI: FFCD 2000-05. J Clin Oncol 2010; 28: 2556-2564.
16. Funke S, Timofeeva M, Risch A, Hoffmeister M, Stegmaier C, Seiler CM, et al. Genetic polymorphisms in GST genes and survival of colorectal cancer patients treated with chemotherapy. Pharmacogenomics 2010; 11: 33-41.
17. Cotton SC, Sharp L, Little J, Brockton N. Glutathione S-transferase polymorphisms and colorectal cancer: a HuGE review. Am J Epidemiol 2000; 151: 7-32.
18. Csejtei A, Tibold A, Varga Z, Koltai K, Ember A, Orsos Z, et al. GSTM, GSTT and p53 polymorphisms as modifiers of clinical outcome in colorectal cancer. Anticancer Res 2008; 28 (3B): 1917-1922.
19. Rajagopal R, Deakin M, Fawole AS, Elder JB, Elder J, Smith V, et al. Glutathione S-transferase T1 polymorphisms are associated with outcome in colorectal cancer. Carcinogenesis 2005; 26: 2157-2163.
20. Lilla C, Verla-Tebit E, Risch A, Jäger B, Hoffmeister M, Brenner H, Chang-Claude J. Effect of NAT1 and NAT2 genetic polymorphisms on colorectal cancer risk associated with exposure to tobacco smoke and meat consumption. Cancer Epidemiol Biomarkers Prev 2006; 15: 99-107.
21. Jansen L, Hoffmeister M, Chang-Claude J, Koch M, Brenner H, Arndt V. Age-specific administration of chemotherapy and long-term quality of life in stage II and III colorectal cancer patients: a population-based prospective cohort. Oncologist 2011; 16: 1741-1751.
22. Arndt V, Merx H, Stegmaier C, Ziegler H, Brenner H. Quality of life in patients with colorectal cancer 1 year after diagnosis compared with the general population: a population-based study. J Clin Oncol 2004; 22: 4829-4836.
23. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988; 16:1215.
24. Neuhaus T, Geisen G, Bolt HM, Janzen V, Kraemer A, Vetter H, Ko Y. Reliability of non-invasively acquired human genomic DNA as a substrate for real-time PCR-assisted analysis of genetic polymorphisms. Arch Toxicol 2004; 78: 390-396.
25. Timofeeva M, Jager B, Rosenberger A, Sauter W, Wichmann HE, Bickeböller H, Risch A. A multiplex real-time PCR method for detection of GSTM1 and GSTT1 copy numbers. Clin Biochem 2009; 42: 500-509.
26. Schemper M, Smith TL. A note on quantifying follow-up in studies of failure time. Control Clin Trials 1996; 17: 343-346.
27. Hong J, Han SW, Ham HS, Kim TY, Choi IS, Kim BS, et al. Phase II study of biweekly S-1 and oxaliplatin combination chemotherapy in metastatic colorectal cancer and pharmacogenetic analysis. Cancer Chemother Pharmacol 2011; 67: 1323-1331.
28. Chen YC, Tzeng CH, Chen PM, Lin JK, Lin TC, Chen WS, et al. Influence of GSTP1 I105V polymorphism on cumulative neuropathy and outcome of FOLFOX-4 treatment in Asian patients with colorectal carcinoma. Cancer Sci 2010; 101: 530-535.
29. Nelson HH, Wiencke JK, Christiani DC, Cheng TJ, Zuo ZF, Schwartz BS, et al. Ethnic differences in the prevalence of the homozygous deleted genotype of glutathione S-transferase theta. Carcinogenesis 1995; 16: 1243-1245.
30. Dorion S, Lambert H, Landry J. Activation of the p38 signaling pathway by heat shock involves the dissociation of glutathione S-transferase Mu from Ask1. J Biol Chem 2002; 277: 30792-30797.
31. Cho SG, Lee YH, Park HS, Ryoo K, Kang KW, Park J, et al. Glutathione S-transferase mu modulates the stress-activated signals by suppressing apoptosis signal-regulating kinase 1. J Biol Chem 2001; 276: 12749-12755.
32. Wang T, Arifoglu P, Ronai Z, Tew KD. Glutathione S-transferase P1-1 (GSTP1-1) inhibits c-Jun N-terminal kinase (JNK1) signaling through interaction with the C terminus. J Biol Chem 2001; 276: 20999-21003.
33. Adler V, Yin Z, Fuchs SY, Benezra M, Rosario L, Tew KD, et al. Regulation of JNK signaling by GSTp. EMBO J 1999; 18: 1321-1334.
34. Jankova L, Robertson G, Chan C, Tan KL, Kohonen-Corish M, Fung CL, et al. Glutathione S-transferase Pi expression predicts response to adjuvant chemotherapy for stage C colon cancer: a matched historical control study. BMC Cancer 2012; 12:196.
35. Tan KL, Jankova L, Chan C, Fung CL, Clarke C, Lin BP, et al. Clinicopathological correlates and prognostic significance of glutathione S-transferase Pi expression in 468 patients after potentially curative resection of node-positive colonic cancer. Histopathology 2011; 59: 1057-1070.
36. Hu X, Xia H, Srivastava SK, Herzog C, Awasthi YC, Ji X, et al. Activity of four allelic forms of glutathione S-transferase hGSTP1-1 for diol epoxides of polycyclic aromatic hydrocarbons. Biochem Biophys Res Commun 1997; 238: 397-402.
37. Zimniak P, Nanduri B, Pikula S, Bandorowicz-Pikuła J, Singhal SS, Srivastava SK, et al. Naturally occurring human glutathione S-transferase GSTP1-1 isoforms with isoleucine and valine in position 104 differ in enzymic properties. Eur J Biochem 1994; 224: 893-899.
38. Braun MS, Richman SD, Thompson L, Daly CL, Meade AM, Adlard JW, et al. Association of molecular markers with toxicity outcomes in a randomized trial of chemotherapy for advanced colorectal cancer: the FOCUS trial. J Clin Oncol 2009; 27: 5519-5528.